CRBG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CRBG is not a good buy right now for a beginner long-term investor with fresh capital, despite some supportive analyst targets and positive congress buying. The stock is under pressure from AIG’s large share sale, hedge fund selling, and weak latest-quarter profitability, so the current setup is not attractive enough to call an immediate buy. If the investor is impatient and wants to deploy capital now, I would still avoid buying today and wait for clearer confirmation of earnings recovery or a better entry after the current supply overhang is absorbed.
The trend is neutral to slightly weak. Price closed at 27.20, below the previous close of 27.45, with the regular session down 2.14%. RSI_6 at 53.4 is neutral, MACD histogram is positive at 0.111 but contracting, and moving averages are converging, which suggests momentum is fading rather than strengthening. Key levels are pivot 27.405, resistance 28.413/29.037, and support 26.397/25.773. In short, the stock is range-bound and lacks a strong bullish breakout signal.
["Mizuho raised its price target to $35 and kept Outperform.", "Keefe Bruyette raised its target to $38 and kept Outperform.", "Corebridge declared a quarterly dividend of $0.25 per share.", "Congress trading data shows 1 purchase and 0 sales in the last 90 days, a positive signal.", "Revenue in Q1 2026 grew 10.42% YoY, showing top-line expansion."]
["AIG is selling about 25.46 million shares, creating a large supply overhang.", "Hedge funds are selling heavily, with selling up 2778.97% over the last quarter.", "Q1 2026 net income was negative at -$53 million and EPS fell sharply to -0.11.", "Several analysts lowered price targets recently, including UBS, Mizuho earlier in April, Barclays, and TD Cowen.", "The stock price action is weak, with the market down 2.14% on the session."]
In Q1 2026, Corebridge posted revenue of $3.964 billion, up 10.42% year over year, which is a solid growth sign. However, profitability weakened materially: net income came in at -$53 million versus a profit last year, and EPS declined to -$0.11. For a long-term beginner investor, the growth in revenue is not enough to offset the sharp earnings deterioration in the latest quarter season.
Wall Street is mixed but still leaning constructive overall. Recent upgrades/positive target revisions came from Mizuho and Keefe Bruyette, both maintaining Outperform, and BofA still has Buy, though with a lower target. At the same time, UBS cut its target and kept Neutral, and multiple firms reduced targets in April. Pros: several firms still see upside to $35-$38. Cons: target cuts across the group show caution on life insurers, and recent revisions reflect softer expectations. Overall, analysts are supportive but less uniformly bullish than before.
